10 Leading Diagnostic Solution Providers 2019

1. Vol. 5 /Issue-1 www.insightscare.com May2019 10 Leading Diagnostic Solution Providers2019 RobertHuffstodt President & CEO Empowering Providersthrough Point-of-careTesting

4. Editor-in-Chief Pooja M.Bansal Senior Editor AnishMiller Managing Editor AshwiniS.Deshpande Executive Editor AishwaryaNawandhar Contributing Editors Sayali Rane, SnehaSinha Visualiser DavidKing Art & Design Head AmolKamble Art & Design Assistant PoonamMahajan Co-designer PaulBelin Art & Picture Editor RahulKavanekar Business Development Manager PeterCollins Marketing Manager MarryD'Souza Business Development Executive MarkWilliams Sales Executives Amy, John, Bill,Sarah Technical Head JacobSmile Assistant Technical Head PratikshaPatil Technical Consultants David,Robert Digital Marketing Manager AlinaSege Assistant Digital Marketing Manager PrashantChevale SME-SMO Executives Manoj, Gemson,Uma Research Analyst EricSmith Circulation ManagerTanaji sales@insightscare.com May,2019 CorporateOfces: Insights Success MediaTechLLC 555 Metro Place North,Suite100, Dublin, OH 43017,UnitedStates Phone -(614)-602-1754 Email:info@insightscare.com For Subscription:www.insightscare.com Insights Success Media and Technology Pvt. Ltd. Ofce No. 22 & 510, Rainbow Plaza, ShivarChowk, Pimple Saudagar, Pune, Maharashtra 411017 Phone - India: 7410033802,74100058552 Email:info@insightscare.com For Subscription:www.insightscare.com Copyright © 2019 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any formorby anymeans,electronic,mechanical,photocopying,recordingorotherwise,withoutpriorpermissionfromInsightsSuccess. Reprint rights remain solely with InsightsSuccess.

5. Editor’sColumn iagnosis is a very crucial part of the treatment ofany Dreachingtherealproblem is very difficultandguesswork health related disorder. Without properdiagnosis, based treatment methodology in the medical field cansometimes be very dangerous. The field of diagnostics is advancing and many new techniques have come up that are taking us towards precision medicine and patient personalized solutions. The technique that has grabbed a lot of attention in the last fewyears is molecular diagnostics. In simple terms, it means theanalyzing of a patient is done at molecular level. Molecular diagnostics involve examination of the biological markers in a person’s genome (genetic code), testing of DNA/RNA sequences for identification of the disease, cellular testing,etc. It allows the detection of pathogens in a human body as well as genetic testing. In pathogen detection, molecular diagnosis searched for signs of pathogen-derived nucleic acids in the patients and hence, helps identify the infection. In genetictesting, mutation of the cells, genetic disorders, chronic diseases, etc. can be diagnosed. Molecular diagnostics can truly revolutionize care by helping us move towards accuracy and personalizedmedicine. Molecular diagnostics field has seen rapid and large growth in the past few years and it is predicted that it will continue to do so further. This owes to the advantages it brings, which include accurate, analytically sensitive, and fast detection as well as monitoring of a number of diseases. Today, there are varioustools and technologies available for this and it doesn’t stop here, there is so much more to explore. Molecular diagnostics has not just enabled disease characterization, but it goes a step ahead and has enabled patientcharacterization. Used particularly in the fields of oncology, infectious diseases, and congenital abnormalities, clinical pathology at the molecular level is improving patient monitoring and management. In 2017, the global market for molecular diagnostics was reported to be valued at $7.5 billion and this is expected to go up to $15.6billion by 2024. With new infection and chronic diseases coming up every day, it has emerged to a very important revolution in healthcare. Molecular diagnostics has the potential to aid early detection and diagnosis of diseases as deadly as cancer and the further advancements in this field comes with a promise of a bettertomorrow! Futureof Medical Diagnosis- Going Molecular! AishwaryaNawandhar Editor

6. The Industry Leaders Transforming the DiagnosticSpace T he first step to treating any health condition is diagnosis. If not diagnosed rightly, a patient maynot receive the needed effective treatment on time and this can lead to major complications inthe future. The significance of correct diagnosis is taught to every medical student from the verystart. Today, healthcare is moving towards personalized medicines and correct detection of the ailment isthe key to reach there. Although it is very important to focus on this segment of the care industry, only twoto three percent of the total healthcare resources are spent on diagnosis, according to a qualifiedreport. There are few prominent companies that are remarkably transforming the diagnostics industry withtheir innovative tools, technologies, and techniques and taking us closer to personalized healthcare. In our special issue of “10 Leading Diagnostic Solution Providers 2019”, we have featured top diagnostic companies that have not only enabled correct detection of diseases but have aided in early diagnosisand are contributing largely to the better tomorrow ofhealthcare. Featured on the cover of this issue is PTS Diagnostics. It is revolutionizing the diagnostic industryby innovating point-of-care with people, technology, andservice. Other than the insightful cover story, we have also featured the top industry leaders dedicated to provide enhanced diagnostic care to all. These include BioDirection, a medical device company that develops state-of-the-art point-of-care products to manage traumatic brain injuries and concussions; Biolumo thatis focused on developing a set of tools for fast and inexpensive antibiotic resistance detection;Colorimetrix, which develops testing applications that turn smartphones into portable labs, enabling the semi- quantitative measurement of diagnostic tests at home; Genomic Expression, a leading organization that sequences RNA to identify the best drug for the patient and the best patient for the drug; MedCloud, a patient-centered platform for diagnosis, focused on simplifying test management in all its phases; Exagen Diagnostics; GeneNews; IR2Dx; and NHGDiagnostics. Apart from this, the issue also incorporates an ingenious article from Tania Martin-Mercado, theChief Technology Officer of YGEIA, as well as a few interesting articles from our in-houseeditors. So, walk through the pages and enjoy a good read!

8. CO CoverStory 08 NTEN PTSDiagnostics EmpoweringProviders through Point-of-careTesting AdroitOutlook What Digital Startups Need to Succeed in theHealthcare Space? 28

9. TS ARTICLES IndustryTrends RecentAdvancements in DiagnosticIndustry Editor’s Angle Never Miss aDose: MedicationApps 22 40 BioDirection Unlocking the Powerof Nanotechnology to AddressTBI 16 Biolumo Delivering a Fast Point-of-care Antibiotics SelectionTool 20 26 Colorimetrix Bringing LabDiagnostic Tools to the Hands of Everyone GenomicExpression Improving Care andSaving Lives 32 36 Medcloud Centralizing Datafor DecentralizingCare

10. COVERSTORY RobertHuffstodt President &CEO

11. PTS Diagnostics Empowering Providers through Point-of-careTesting

12. T “ strategies, and partnerships aimedat helping healthcare providers thrive in a rapidly changing industry. Humble Roots Headquartered in Indianapolis,Indiana, with majoroperation he healthcare industry isina period of transitionboth The industry is ina domestically and globally.This period of transition,both is driven by a host of factorsfrom domestically and worldwide. We are transforming alongwith theindustry legislation and regulation to thegrowth of populations with chronic health conditions such as diabetes. Thesearch for adaptive solutions is intense, and the pressure on companies and organizations to innovate and bring new, high-quality solutions to market quickly isstrong. One of the key challenges for healthcare solutions providers, is to develop products and programs that help address the growing demand for chronic disease management in a way that increases efficiency, lowers costs, and increases patient satisfaction. PTS Diagnostics, a provider ofstate-of-the- art point-of-care testing solutions is rising to thechallenge. Through the company’s commitment to customer focus, innovative technology, and adherence to robust quality standards, they have established themselves as a leader in the manufacture of fast, accurate, and portable point-of-care testing devices. And, they have recently begunbuilding more on that strong foundation with PreVantageTM, a suite ofproducts, “ centers inSunnyvale, California, PTS Diagnostics was founded in 1992 by an individualwho had been affected by diabetes. As a patient, he saw how small, portable glucose meters could quickly and conveniently measure blood glucose levels. He soon realized that therewas an unmet market need for a similar device that could that could measurea number of additional chronic disease risk indicators, such as blood cholesterol and ketonelevels. In its early days, PTS Diagnostics was a one-man shop, run out of the founder’s home. Within a couple of years, enough angel funding wasraised to move to a business building andhire additional people. In 1997, the company moved to its current location, where more office and lab space was gradually added over the next 25 years as the companygrew. In 2013, PTS Diagnostics acquired A1CNow® from Bayer. In 2016, itwas acquired by its currentparent company,Sinocare. The company has now expanded to such anextent that it has outgrown its current location, andwill move into a brand new, 145,000 square-footfacility in the Spring of2019. Over the years, the company placed a great deal of focus on growth and profitability,while holding on to its identity and its reputation for quality service. Itfought against all odds to find its place in the market, and managed to get where itis now through perseverance and angel investments. “I’m immensely proud of this,”asserts CEO RobertHuffstodt. PassionateLeadership PTS Diagnostics is led byPresident and CEO Robert Huffstodt, he isa Notre Dame graduate with a background infinance. He considers himself very lucky to have had the opportunity to lead a number of organizations early in his career. Being assigned the task of conducting financial audits forstartups and smaller companies helped him gain a thorough understanding ofwhat made these organizationstick. “When I moved out of public accounting and into the private world, I again found myself at a startup. It was here where a mentor gave me the opportunity to dip my toe into every discipline, from sales calls to factory management,” he says. This gave him a flavor of what it was like to run a whole business from top to bottomand has directly contributed to his success with PTSDiagnostics. Huffstodt has also always had an affinity for international business. This has served him well as thereceptivity

13. to PTS Diagnostics’ products indozens of markets around the world has continued togrow. On the personal side, Huffstodt has a passion for music, art, andarchitecture. These interests have inspired him to create an environment within the company’s new global headquarters that is conducive to creativity and innovation. People, Technology, and Service The company’s name represents the three pillars upon which it has builtits long-term success: People, Technology, andService. ‘People’ starts in-house with the skills, talents, and energy of PTSDiagnostics’ global employees and partners. It extends to its strongly-held value of providing high-quality service, person to person. That’s why the company intends to always have real humans answering its calls. “It sends the signal that we’re approachable and are about people,” saysHuffstodt. ‘Technology’ points to the company’s innovative products and solutions.PTS Diagnostics integrates old technology and new technology to develop products that are accurate, reliable,and easy to use. Huffstodt says, “We’re not trying to release new updates just because we can. Pairing well-tested elements with modern updates that we believe in allows us to have the best of both worlds.” Since PTS Diagnostics has been focused on perfecting itscraft instead of always rushing to thenewest thing, many of its technologies and products have stood the test oftime. ‘Service’ also has a dual meaning. Internally, the company prizes excellent service provided among departments and employees, but it takes particular pride in the level it service it strives to provide to the customer, which ranges fromtraining to logistics and other elements of its business. As thecompany moves beyond its products,and toward more comprehensive services and solutions with PreVantage, service will take on yet another level of significance. Flagship Products PTS Diagnostics’ signature products include the CardioChek® analyzer and the A1CNow® test system . Both products stand out in the market by being incredibly portable, efficient, and accurate. They also recently launched PreVantage which aims to enhance those products with added convenience, connectivity, and extended servicefeatures. With PreVantage, CardioChek and A1CNow are not mere devices—they are part of a solutions package that links to Electronic Medical Record (EMR) systems, which are the backbone of many of todays’ healthcare organizations. Thebundled PreVantage product and connectivity offerings are intended to help healthcare organizations transition from Fee for Service payment models to Value-Based Paymentmodels. Otherproducts The company also offers the PTS DetectTM cotinine system, PTS CollectTM capillary tubes, andPTS ConnectTM solutions. technology and innovation to blood collection. And, PTSConnect ProLink and PTSConnect ScreenPro simplify point-of-care health data collectionand transfer for health and wellness companies, retail clinics, and urgent carecenters. What Sets PTS Diagnostics Apart The creative business approaches and the collaborative spirit behind PTS Diagnostics are what allows it towork with partners all over the world and continue to grow year afteryear. The company is also unusual in that it has succeeded largely on its own, without venture capital or a large benefactor. It has bootstrapped itselfon angel money, survived, andthrived. The history and background of the company has placed it in a unique position to serve new healthcare delivery and payment systems.PTS Diagnostics envisions becominga PTS Detect cotinine is the first and only quantitative tobacco-detection system that can measure exact cotinine levels from a simple fingerstick. PTS Collect capillary tubes brought newnew “The growth ofour organization will comefrom organic growth in our markets, expansion of product offerings, broader menus, andmore “

14. “ We strive to be innovative in our business models and practices,as well as our products, and to create a situation where everybody wins, from the employees and internal stakeholders toour business partners, to end users, patients, and society atlarge “

15. “Wewanttoachieveconsistent profitable growth while maintaining our focus on providing products and services that benefit theconstituents “ global leader in providing innovative, point-of-care products and services that aid healthcare providers intheir preventative healthcare and chronic disease management efforts. Other factors that set PTS Diagnostics apart from its competitors are its size, its promptness, and its resourcefulness. As a company, PTS is the right size to provide customers with flexibility and personalized service. “We’re not so big as to be rigid, ponderous, and slow to react, on the other hand, we’re not so small as to have too limited of resources” Huffstodt says. “Service and going the extra mile make us standout.” An Insight into ‘ProductTraining’ PTS has a multitude of tools that enhance its training process for both professional and home users “We have a range of options available and we don’t pigeonhole customers into methods that are unconducive to their learning style or schedule,” says Huffstodt. He continues, “For us as a company, the realization of how importantthat was a watershed moment.” Notable Awards &Accreditations In addition to its numerous product accreditations, PTS Diagnostics has earned recognition for its unique product offerings and continued success. In addition to being listed as one of Inc. Magazine’s 5,000 Fastest Growing Companies six times, the company has also been featured on the Today Show, Doctor Oz, and other similarprograms abroad. Disrupting the Point-of-Care Solution Industry One of the biggest disruptions to the healthcare industryin recent years has been the shift in reimbursement modelsin the United States, specifically the moving away from fee- for-service models toward value-based models that pay based on the efficiency and effectiveness of care. PTS Diagnostics has recognized that outcomes are the new income™ and has the right products mix of product offerings and industry partners to help healthcare organizations make a positive impact on value-based paymentobjectives. The portability and ease-of-use of PTS Diagnostics’ products also position them well to help retailpharmacies, urgent care centers, and community health centers offer lipid panel and A1C wellness testing in a way that often more convenient forpatients. Future of PTS Diagnostics The company is currently in a period of multiple simultaneous transitions. The first is the building of a new headquarters which will be completed in the second quarter of 2019. The launch of PreVantage solutions is also underway and is continuing to grow and evolve as aproduct offering and business model. And, new technological innovations are also in thepipeline. “We certainly believe that we’ll see double digit growthfor the foreseeable future,” asserts Huffstodt.

18. “ Relentlessinnovation for improving thediagnosis and management of TBI is what drives us. We are dedicated to improving treatment plans andsaving more and morelives -SharadJoshi President &CEO “ 16 / MAY 2019/

19. BioDirection Unlocking the Powerof Nanotechnology to AddressTBI Ttotakecare of up to $10 BillionTraumaticBrainInjuries (TBI). CDC estimatesthe raumatic Brain Injuries (TBI) and sports related concussions have become verycommon and are increasing at an alarming rate. There is an enormous unmet global marketneed direct or indirect cost spent on treatment of these concussions to be greater than $76 Billion in the US alone. Over 75 percent of TBI are classified as mild traumatic brain injuries while 90 percent of the people with concussions never lose consciousness. There is a lack of anobjective point-of-injury (POI) or point-of-care (POC) test. TBI testing today is symptomaticdiagnosis, which has a high error rate and is not at all definitive. This is where BioDirection, Inc. stepsin and has the potential to manage the diagnosis in a specific and timelyfashion. BioDirection is a privately held medical device company developing cutting-edge and rapid point-of-care or point-of-injury products for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). It is leveraging the power ofnanotechnology to address the rapid and definitive diagnosis ofTBI. BioDirection Tbit™System The company’s first product Tbit™ System is a whole blood POC or POI test platform for traumatic brain injury. It is rapid and affordable test that generates a result in less than two minutes from a single drop of blood. The system measures targeted brain biomarkersreleased from the brain following a head trauma or jolt to the body. The platform is easy-to-use, portable and low-cost system (affordable), it consists of two components: tabletop or handheld analyzer and a single-use, disposable sensor cartridge.The disposable sensor drives significant revenue – razor blade annuity. Tbit™ System has the potential to generate a high margin business with strong cashflow. BioDirection has exclusive, global rights to a Harvard generated patent portfolio for acquired brain injury and Sepsis plus extensive nano-wire based biosensor design or manufacturing know-how. The system is based on design of nanowire biosensor produced from nanowires.A single nanowire is 1/10,000 of a human hair. Tbit™ System offers ultra-sensitivity and specificity. / MAY 2019 /17

20. pre-revenue start-ups, mid-market companiesto large scale companies, such as Proctor & Gamble. He also has the expertise in creative product development, marketing, and technical sales instrumentation and capitalequipment. Serving Global & DiverseMarket BioDirection estimates up to a 5-Billion-dollar market in USA alone for its products with potential to treat greater 50 Million people around the globe. TBI injury impacts all walks of life and age groups with high potentialtargets extending well beyond sports (all levels –youth, interscholastic, university/college, and professional). Additional targeted markets include military training and deployment, hazardous work environments, senior living or nursing facilities, medical clinics and physician offices, first responders and ambulances, rural medicine, educational facilities, recreation and disasterrelief. BioDirection’s first targeted market is a screen to a CT scan, which it estimates is up to 5 million CTscans for head injury per year in the USA. The company is awaiting its final trial results, which the company believes will approach 100 percent sensitivity to positive CT scans (100% NPV) and ability to detect abnormal protein levels consistent with micro-bleeding not found in negative CT scans. It has already received FDA Breakthrough Device Designation in January 2019. Subject to FDA review and clearance, BioDirection’s first target is to launch Q1 in 2020; this is subject to FDA review and clearanceprocess. Future Road Map & DevelopmentStrategies Moving beyond the screen to CT, BioDirection plans to modify the existing TBI™ System providing the full continuum of care for TBI patients including stratification of injury, prognosis, and post-operative return to activity or play. Additionally, the company is also seeking a partner to develop rapid testing products for sepsis, which alsorequire rapid diagnosis in criticalconditions. It uses the selected GFAP and S100b as initial targeted biomarkers; these are clinically validated over 50-60 years as acute biomarkers for TBI. S100b is approved as a screen to CT in over 20 countries world-wide outside of USA. Tbit™ System is a flexible and versatile platform and isnot biomarker dependent and readily adaptable to new biomarkers. It has full multiplexing functionality, capable of measuring 2, 3, 5, 10 or more biomarkers simultaneously. It is a game changing technology and the company is targeting market entry late Q12020. The OutstandingLeadership Sharad Joshi, the President and CEO at BioDirection isa dynamic leader who fosters a mission-centric, fun, and collaborative environment. He holds B.Sc (Mechanical Engineering) degree with a Pre-Med minor from Northeastern University and graduated cum laude with an MBA from Babson College in Wellesley,MA. He has over three decades of experience in the medical device field including management positions as CEO, President, & COO, Marketing, International Sales, Engineering, among other executive positions. He hasalso been the inventor and author of numerous patents and publications. Sharad has also served as a business advisor or technical consultant at various companiesincluding 18 / MAY 2019/

22. JakubWysocki CMO WojciechGiżowski OlgaGrudniak VP &COO CEO Biolumo Delivering a FastPoint-of-care Antibiotics SelectionTool Amonetary resources as well as alot of companies ntibiotic resistance is a major problem faced bythe success alone, believes Biolumo. It believes in working asa team and with partners. The roles in the company reflectthe responsibilities and skillset, not hierarchy. Biolumo has an amazing team starting with its Chief Science Officer, Marcin Pitek, who came with the idea. Olga Grudniak is the CEO, who combines science and business together. She is very recognized, young businesswoman. Wojciech Giżowski, the COO, is an expert on building both relations and products. He is responsible for the most partnerships and mentors that keep the company going. Jakub Wysocki keeps Biolumo on the lips of both media and investors. All of them have played important roles in the company’s success. The Journey ofBiolumo Post Biolumo’s inception, the first months were devoted to testing its initial idea to identify antibiotics resistance inthe patients’ samples. Since then, Biolumo has evolved this method and designed fully automated prototype that can be used by everynurse. healthcare industry today. It has cost a lotof have invested their time in finding a solution tothis. Biolumo, an innovative and growing company based in Gdynia, Poland, was also set on the same quest. It faced a question from its mentor and business advisor, “Can you point any solution that will make me sure my son got the right antibiotics prescribed?” This question lighted aspark in the company’s team; a spark that started the fire called Biolumo. Today, the company is focused on developing a set of tools for fast and inexpensive antibiotic resistance detection. Founded in 2017, Biolumo has its major operationcenters in Pomerania Science and Technology Park, Gdynia. It offers a diagnostic effectiveness on antibiogram level, delivering results 8 times faster. The Fuel to itsSuccess No one person can achieve true science andbusiness 20 / MAY 2019/

23. It has participated in one of the best acceleration programin the world – Startupbootcamp Digital Health, which helped Biolumo in planning its international growth strategy. In Poland, the company’s country of origin, it has managed to partner up with the biggest healthcare companies on the market. “Our mission, even before the Biolumo conception, was to fight antibiotics resistance the best we can,” says Olga.The want to give scientists time to develop a sustainable successor for traditional antibiotics was the goal of Biolumo’s science team, this also included boosting effectiveness of diagnostics amongst the group that prescribes the most antibiotics, GeneralPractitioners. Unique Point-of-care Solution Biolumo’s flagship product is a fast, point-of-care antibiotics selection device for general practitioners and clinics. The company is offering diagnostic effectiveness on antibiogram level, by delivering results eight times faster. Furthermore, its solution is automated and therefore, easyto use. It can also provide a new revenue stream forclinics. This product is a brilliant combination of biotechnology, hardware, and software. The company has used modern technology instead of XX century method, which allowedit to identify antibiotics resistance much faster. With Biolumo’s ingenious product, a laboratory, trained specialists, or the transporting sample are not needed to reach the results and that minimizes the costsfurther. The company’s interdisciplinary approach and its focuson finding the best combination of these disciplines is thekey factor leading it towardssuccess. Honorary Laurels For its remarkable contribution, Biolumo has been recognized by many national and international organizations highly regarded amongst the healthcare society. One of the biggest distinctions Biolumo has been honoured with was being listed at prestigious Global Digital Health 100 ranking by The Journal of mHealth. It has also been awarded the title - The Healthcare Leader during The XXIII International Open Healthcare Congress by the healthcare key opinion leaders in its region, in January 2018. Biolumo won the 2nd place at infoShare 2018 Startup Contest, the competition that takes place during the biggest startup conference in the CEE region. Furthermore, at the beginning of 2019, its CEO, Olga Grudniak, has been named The Best Entrepreneur in 25 Under 25 by Forbes and The Businesswoman of the Yearin Poland. What’sAhead? Biolumo is working hard to roll out its device, as soon as possible. “We want to give scientists the time to developa sustainable successor for traditional antibiotics – our science team included – by boosting effectiveness of diagnostics,” says Wojciech. After that, it has developed plans for the next features and upgrades in itsproduct. Speaking about the future endeavors, businesswise, Wojciech asserts, “We are working on strategies for international lunch of our device. To get the effects we hope to achieve, we need to provide our solution worldwide, not only in our region.” Simultaneously, the company is continually working on the next generation antibiotic that should be a long-term solution for the problem, which may take some time and resources as developing any new drug does. “ We aim toimprove care for all,by finding an answer to the antibioticresistanceproblem, with an interdisciplinary approach “ / MAY 2019 /21

24. Recent Advancementsin DIAGNOSTIC INDUSTRY 22 / MAY 2019/

25. IndustryTrends hehealthcaresectorismovingfromreactivecaretopreventivecare.Preventive carehelpsthepatienttakenecessaryprecautionstoavoidcertainconditionsand Additionally, the cost of preventive care is much less than that of reactivecare. Diagnosticsis amajorpartofpreventivecare.Alltheconventionaltreatmentmethods mostly follow the trial and error method, where the illness is guessed based on the symptoms the patient shows. It is necessary to move ahead from this method to personalizedcaretoimprovetheoutcomesofhealthcare.Optimumdiagnosisisthefirst step towards this. The diagnostics industry is witnessing immense transformation and therearevariousnewdevelopmentsthatarehelpingitmovetowardspersonalizedcare. Let'slookattherecentdevicestransformingdiagnostics. Talsohelpstheminidentifyingtherootofadiseasebeforeitbecomesserious. BetterDetectionof EbolaViruswitha MicrofluidDevice Ebolaisahighlycontagiousanddeadlyvirusand onceinfected,itleaveslimitedtreatmentoptions forthepatient.Moreover,itcanspreadeasilyand startanepidemic.Tocombatthedangersitbrings to the human lives, scientists at the Rochester InstituteofTechnology(RIT)havedevelopedthe prototype of a novel micro device. This device helps diagnose the infection caused by Ebola early,whichresultsinbettertreatmentoutcomes aswellasreducesthespreadofinfections. The developed microfluid device hasbiosensors attached to it. It is a small, automated chip that has fluorescence sensors attached to it. The devicedetectstheEbolaRNAwhenthepatient's sample is added to it by activating the CRISPR mechanism.Theresearchersarefurthertryingto find a way to generate this device at affordable costs. / MAY 2019 /23

26. KidneyIntelX- ABreakthrough Device KidneyIntelX is the main diagnostic test for kidney diseases devised by Renalytix AI plc. It exhibits promise to improve the clinical management of patients with fast-growing kidney diseases and type-2 diabetes. It helps in better diagnosis and well as treatment ofthese. KidneyIntelX uses machine learning algorithms toexaminethecombinationofpredictiveblood- based biomarkers. These include sTNFR1, sTNFR2, and KIM1 along with the electronic health record data. The device is designed to identify the progressive kidney disease. It was designatedasaBreakthroughDevicebyFDA. Q-POC– ARevolutionary DiagnosticsKit KidneyIntelX is the main diagnostic test for kidney diseases devised by Renalytix AI plc. It exhibits promise to improve the clinical management of patients with fast-growing kidney diseases and type-2 diabetes. It helps in better diagnosis and well as treatment ofthese. KidneyIntelX uses machine learning algorithms toexaminethecombinationofpredictiveblood- based biomarkers. These include sTNFR1, sTNFR2, and KIM1 along with the electronic health record data. The device is designed to identify the progressive kidney disease. It was designatedasaBreakthroughDevicebyFDA. 24 / MAY 2019/

27. ARemarkable DNASequencing Device-MinION MinION, a new DNA sequencing device by Oxford Nanopore, can detect the Huntington's disease a lot faster than the traditional ways. It could therefore drastically reduce the waiting timefornumberofcriticalcasesofHuntington's disease,aswellasothergeneticdisordersinthe future.Moreover,itmeetsthestrictinternational qualitystandardsforlaboratoryuse. MinION is a small device which decodes every DNA strand separately in real-time. This hand- helddevicecanthenidentifythechangesinany DNA sequence to detect the genetic disorder. Beingabletodoallofthisinreal-time,thedevice cutsdownthewaittimefortheresults. MassSpec- Promiseofa BetterTomorrow MinION, a new DNA sequencing device by Oxford Nanopore, can detect the Huntington's disease a lot faster than the traditional ways. It could therefore drastically reduce the waiting timefornumberofcriticalcasesofHuntington's disease,aswellasothergeneticdisordersinthe future.Moreover,itmeetsthestrictinternational qualitystandardsforlaboratoryuse. MinION is a small device which decodes every DNA strand separately in real-time. This hand- helddevicecanthenidentifythechangesinany DNA sequence to detect the genetic disorder. Beingabletodoallofthisinreal-time,thedevice cutsdownthewaittimefortheresults. The medical diagnostics industry is advancing at a fast-paced. The new innovations come witha promisetoenhancetheaccuracyofdetectingdiseasesinahumanbodyinreal-time.Moreover,the easeofuse,simplicityinmanufacturingaswellastheaffordabilityofthelatestdevicesisimproved. -Aishwarya Nawandhar,Editor / MAY 2019 /25

28. Colorimetrix Bringing Lab Diagnostic Tools to the Hands ofEveryone Ourmi“ssionis tohelpconsumers with direct access to healthcare tools they can use athome Dominik Westner |CTO Dr. Leo Martinez |CEO riven with the passion of ‘Makingdiagnosticlab tools accessible to everyone’, Colorimetrixwas “ D of Innovators under 35 by the MIT Technology Reviewin 2014 for the technology. Mr. Westner, on the other hand, is a seasoned software entrepreneur, with a successful exit to Blackberry in 2011. They both are spearheading Colorimetrix with their inimitable talent and haveachieved milestones together to bring ‘Pearl Fertility’ to the market (www.pearl-fertility.com). The Story ofColorimetrix Colorimetrix started as a small project, as the lab in pocket or pocket diagnostics. While Dr. Martinez was working in the lab, he broke a spectrophotometer machine, which is a very expensive and bulky machine, which made himrealize that most of the machines required in healthcare procedures are heavy, weight-wise as well as cost-wise. He then started dreaming of making them obsolete with software and small hardware and then realized that almost all they doisalready included in a mobile phone. Since then, Dr. Martinez and his partner Dominik started working onmultiple established in 2014, and officiallystarted commercial operations in 2017. Colorimetrix decidedto help women seeking to get pregnant with their firstproduct ‘Pearl Fertility’ released to the market in 2018. Since then, its drive has been the same, to bring knowledge forward, where it is most needed, in the hands of consumersseeking information about their bodies in a more personalized and understandingway. ‘Pearl Fertility’ is a self-monitoring kit to test hormones at home. Women can see their hormones rise and fall during their cycle and get personalized information. For couples who are trying to conceive, this is crucial, as knowingwhen the fertile days are based on reliable accurate predictions, can lead to kick starting a new, wonderful journey. About the Duo Dr. Leo Martinez is the CEO and Dominik Westner isthe CTO of Colorimetrix. Dr. Martinez was included in thelist 26 / MAY 2019/

29. applications of the technology. The number of potential applications was vast and broad, after a lengthy processof defining the product that is when finally the decision was made to go with Pearl Fertility- Colorimetrix’s firstn product, ovulation and fertility tracking at home, the first fertility test that includes up to three individualhormones. Awards and Recognitions Apart from the MIT Innovators under 35 Award, Colorimetrix holds the ‘Seal of Excellence’ from the European Commission for top SME companies. The company has also been a part of the ‘Mass Challenge Accelerator in Switzerland’ and is a Grantee of the EIT- Health in Europe. Colorimetrix was also a part of the Google Launch Pad for startups in Germany, and hasgained recognition in various pitching events inEurope. Testimonials The true success of any company is measured by the number of its happy clients. Colorimetrix has been an essential part of its clients’ journey and they speak really highly of the company’s ovulation tests kit, PearlFertility: “We used this product to confirm ovulation which we measure using LH test sticks. This was an easy to use test- the main catch is to remember that you’re looking foronly one line to confirm progesterone, rather than the standard two lines of other positive tests!”- Amazon fromDanielle “We are very happy to share with you the joy of having a baby and let you know that Pearl was of great help inthe journey, every test strip we took was worth the effort”- Fernanda,Nutritionist Simplifying Life of Patients andPhysicians Colorimetrix says that it is easy to misuse theword‘patient’ in the Fertility topic. The truth is that many peopleare immediately classified as infertile because of the lack of consensus and the lack of knowledge in the fertility space. In reality, there are several conditions that affect fertility, and it does not necessarily mean they make you infertile, some are treatable and some may just lead to one taking longer journeys to conceive, but not necessarily make one infertile or in need of IVF right away. The company believes that patients are often left alone after the doctor’s visit and the doctor tells them to keep trying back athome, but there is no way for the doctor to be there with them in those moments of frustration anddespair. “The medicine of the future is the one that comes to you, when the doctor comes to you, when the lab comes to you, when the hospital comes to you. We are just providing a small piece of the puzzle in the future of medicine. Thatone that is personalized, predictive, at home” deliversDr. Martinez. Future Plans Colorimetrix is planning to bring more interesting toolsfor self-monitoring at home to the market. It is also likely to expand its focus from the fertility space to other segments of concern. Also, the company is helping enterprises with solutions for their daily testing routines outside of the healthspace. On asking him about the positive trends going on in the diagnostic industry, Dr. Martinez said, “Diagnostics at home, that is the key, that is the trend. Not to mention thatit has to be personalized, perhaps an old trend but the one so many companies forget to address still. This is what we are doing.” While talking about the future goals of Colorimetrix, Dr. Martinez said, “The clinic, the lab, the medic, comes to you, that is the future we are building up here. Fertility is our first topic, there are many more to tap into.” / MAY 2019 /27

30. Digital Needto in the Space? AbouttheAuthor Tania Martin-Mercado, PhD, is the Chief Technology Officer of YGEIA, a digital healthcare company focused on home healthcareandchronicdiseasemanagement. SheholdsvariousdegreesinIT,healthcare,as wellasbiotechnologyandisseasonedwitha lotofexperienceatvariousprestigiousposts throughout the years. Being a curious soul andalways been fascinated with technology, Tania has been a part of various healthcare innovations. 28 / MAY 2019/

31. AdroitOutlook Tania Martin-Mercado Chief Technology O¶cer YGEIA / MAY 2019 /29

32. ehearalotofbuzzintheindustryandinthemarketplaceaboutthelatestindigitalhealthcare.ehearalotofbuzzintheindustryandinthemarketplaceaboutthelatestindigitalhealthcare. Fromartificialintelligence,machinelearning,remotepatientmonitoringandwearable ofthemosttransformativehealthcaretrends. Wtechnologytohomemonitoringanddata,data,data–digitalhealthcarehasmorphedintoone Whilethisisoneofthemostexcitingtimestobeinthedigitalhealthcaremarket,startupsfocusedonthis space need to make sure their product and service have three-fold impact: Improved patient outcomes, reducedcostofdelivery,andqualityofcare.Cost,qualityandpatientexperienceoftengounnoticedor ignoredinfavoroftechnicalfunctionality.Thelatestandgreatestdigitalhealthcaretechnologywillfailif thepatientsdon’tunderstandhowtouseit,providerscan’timplementitintotheirworkflow,andpayors won’treimburseforitsuse. Bystartingwithapatient-centeredfocus,digitalstartupswillfindtheymayneedtoslowdownandgeta betterunderstandingofthehealthcareindustry,whichoperatesdifferentlythanthetechworld.Thereare more stakeholders in healthcare that need consideration: doctors, patients, insurers, regulators; each of these stakeholders holds a unique perspective on the technology being adopted. Healthcare is complex becausepatientsarecomplex.Asdigitalstartupsfocusononearea,suchasaparticulardisease,theymay stumbleontothemultiplefactorsthatcontributetothatdisease,whatinsurersdoanddon’tcoverrelated to that disease and its symptoms, and more variables that directly or indirectly affect their product or service.Thedevelopmentofaproductorservicerequiresresearchintoclinicalpractice,medicalstudy, patientanddoctorinterviews,andseveralfocusgroups.Digitalhealthcarestartupsneedtohavepatience –somethingthatisunattractivetosomeinvestors,causingdigitalhealthcarestartupstorushintoproduct developmenttooquickly.Instead,involvingkeystakeholdersearlyinthedevelopmentprocessandfully understandingtheconcernsandperspectivewillallowthesestartupstoimpactthehealthcarespacewhere itmattersmost–patientcare. TheMedicalFuturistpublishedafantasticarticleearlierthisyearthathighlightswhyhealthcarestartups fail. Forgetting about the patient, not including the provider, difficulty creating clinical value and overclaimingwhatthetechnologycandoareajustafewofareasdiscussedinthisarticle. Another area often overlooked by digital healthcare startups is the need to integrate. Healthcare data is massive,andthereisno“centralrepository”todrawfrom.Byunderstandingandembracingtheneedfor shared services, integration with other startups or providers in the healthcare industry can foster innovation and better meet patient need or demand. Instead startups may focus on siloed solutions that make it difficult for providers to implement into their practice, thus not offering value to the patient. By understanding how patient data is viewed from a provider and payor perspective, digital healthcare startupswillfindouthowtheirproductorservicewillbemostuseful. Thisissuchanexcitingtimetobeinthehealthcarespace.Thesatisfactionofmakingapositiveimpactin communitiesbyimprovingpatientcareiswhymanystartupsdiveintothehealthcarespace.Bytakinga fewofthesepointsintoconsideration,digitalhealthcarestartupswillfindtheirendeavorsbearingfruit. 30 / MAY 2019/

34. Genomic Expression Improving Care and SavingLives Weem“phasize on the patientfirst and aim to create a companythat respects theindividual Gitte Pedersen | CEO & Co-founder and embracesdiversity “ H Founders Network, XTC (Richard Branson), MolecularTri Conference, Red Herring,andMedTech Innovator. It has also been felicitated withthe ‘Lyfebulb-Helsinn Award’, ‘EIC Life Science Award’,and ‘EUTop50’, and Gitte has presented at the European commission as well as at the UnitedNations. A Journey that Brought Innovation Genomic Expression was started with a large grant fromthe Danish Government as the diagnostic partner of “Genome Denmark”. Gitte and Morten then leveraged that success to raise its first round. With just a patent and an idea in handat that time, the team travelled over the “valley of death” by raising grant money. Today, the company has 4 fullyfunded clinical programs validating its platform - OneRNA™, in four different cancer types with a strong focus on women’s cancer first - all funded bygrants. Genomic Expression could achieve this level of backing because of its ground breaking data. “We identifymarker for a handful of already approved drugs in 100% ofthe eadquartered in Beverly, MA, and foundedin 2012, Genomic Expression is aprominent organization that sequences RNA to identifythe best drug for the patient and the best patient for thedrug. The company is spearheading with a vision torevolutionize healthcare by truly individualizing it, which in oncology means selection of effective treatments that either cure cancer or at least make it chronic and not a deathsentence. The company was established by Gitte Pedersen, the CEO and Co-founder, and her brother Morten Pedersen, after their mother was diagnosed with cancer. Gitte and Morten both are scientists and they knew that the diagnosis was a death sentence if they followed the standard of care guidelines. As a result, they searched for a better drug in clinical development. However, in order to figure outwhich clinical trial could potentially benefit their mother, they needed to better understand the tumor’s genetic profile. For that, they looked for a tool that could do the analysis on a large scale and such a tool did not exist. This gave them a kick-start to incept GenomicExpressions. Today, the company has top placements inWomen’s 32 / MAY 2019/

35. patients by sequencing RNA instead of DNA. This is truein any cancer type. In a world where only 1 out of 4 cancer treatments actually prolongs life, we believe we cangreatly improve outcome and reduce recurrence, and that is what we want to prove in these clinical programs,” assertsGitte. She further continues saying, “We also believe thattreating patients with drugs that actually work as a first line of treatment will decrease cost of care, since managing the side effects for some of the more toxic drugs are expensive, and cost of losing mothers and fathers is significant cost to the society.” OneRNA™: A Unique Flagship Product of thecompany Genomic Expression’s OneRNA™ sequencing platform enables a paradigm shift from ONE disease, ONE marker, ONE drug to ONE patient, MANY markers, MULTIPLE treatment options that go beyond drugs by sequencingRNA and linking data totreatments. OneRNA™ is positioned to disrupt the current standard of care paradigm which only prolongs life for 1 out of 4 patients in oncology, while we are spending $100billion on drugs and 8 million patients die. Using the existing drugs as the toolbox, the company believes that it can prolong life for most patients and in contrast to drugs, clinical approvals can be obtained in less than 12month. Thus, this paradigm shift is a breakthrough because itcan select the best drug for the patients’ real-time problems. For an instance, new drugs get approved or enter into clinical trials all the time and if there is a match between the tumor and this new drug, information can be pushed to the patient’sdoctor. Besides, OneRNA™ is a platform that integrates workflow from RNA extraction in FFPE samples, proprietary RNA-seq library generation, usingIllumina sequencing and proprietary algorithms to analyze the data and several proprietary databases. It enables the identification of aberrantly expressed genes through to the clinical interpretation. This platform is exponentially scalable and can be moved into other indication with an update to the clinical database. The development of this platform has been enabled byNext Generation Sequencing and AI/Big dataanalytics. Until now, the company has raised +$6.5M in grantsto validate OneRNA™ in 4 types of cancers, from the Danish Innovasion Fund, EuroStars, andHorizon2020. Happy Clients at GenomicExpression The true award for any company is its happy clients. Genomic Expression has received numerouspositive feedbacks from its satisfactoryclients. “Measurement of gene transcription through quantitative measurement of RNA sequencing, as made possible by Genomic Expression’s approach, will add significantlyto current methods to characterize the molecular featuresof individual cancers and guide personalized therapy.”- Dr Shridar Ganesan, Rutgers CancerCenter “Being able to identify responders and non-responders to novel treatments by analyzing blood in combination with the OneRNA™ platform has the potential to further improve care and reduce cost. Being able to substitute a highly invasive and expensive biopsy with a blood-based biomarker assay is not only beneficial for the patient, but also potentially able to reduce cost of care.”- DrJonathan Hernandez, TheNCI Future Plans Genomic Expression would be launching OneRNA™ this year while its mission is to get the test into standard ofcare in women cancer first. The company has at least three data packages that are being published over the next couple of years. The company is planning to expand internationally and wishes to address all cancer indications where there is an unmet need, through partnerships and also by raising additionalcapital. The company can also move into other indications, suchas autoimmune inflammatory diseases and all the way to health monitoring and would be focusing more on revolutionizing the healthcaresystem. / MAY 2019 /33

38. Centralizing Datafor DecentralizingCare Medcloud “ Medcloud aimsto Offerthenextgenerationof Cloud servicesfor Diagnostic Management,by accelerating thetransitionof diagnostic centers and hospitalstotheCloud “ Dimas Francisco Silva Jr. |CEO T echnologies like Cloud and I.A hasbeen determining the future of almost allthe • through a worldwideimaging center cloudplatform. • The Unique Products and Services Offered • For imaging centers, Medcloud is a patient-centered platform for diagnosis, focused on simplifying test management in all its phases. Unlike other medicalimaging solutions, Medcloud offers customizable and integrated solutions for any kind of medical tests, combining in a single application all the required tools for diagnosticteams and a mobile way to share the test results. Using its patient- doctor portal, patients can listen to the voice ofaradiologist explaining test results in simple terms, keeping medical history centralized and sharable. The company has developed a cloud platform solution for tests and medical reports. Some of the features of this platformare: • Send or receive tests from any location easily, storingthem fulltime with automated backuproutines • Access tests, anytime, anywhere, through a flexible management and reportingtool • Share tests with patients and doctors, engaging them through a modern patient portal andApp industries and the diagnostic solution industryisn’t different. The big volume of data, the instant accessof information and the constant increase of computationpower has enabled a new era for I.A in Healthcare. One such eminent company that has integrated these technologiesin its functioning is Medcloud. Cloud and I.A is a natural move for Medcloud. Headquartered in São Paulo, Brazil, with its operation center in Rio de Janeiro, Medcloudwas established in the year2012. PACS and medical systems imaging has been prettymuch the same for the past 25years. Interoperability issues, high costs, and a lackof understanding about the role of thepatient in a diagnosis context. These points have defined limits for the patient-doctor relationship and barriers for radiology workflows. Medcloud is committed to revolutionize that through a care-coordination solution that improves workflows for providers and integrates doctors andpatients to a better care. As diagnosis has been a part of the patient journey, it is working on empowering millions oflives 36 / MAY 2019/

39. Medcloud respects the privacy of patient data and hasways of using clinical, demographic and statistical data in the prevention of diseases and monitoring of chronic patients. Besides that, Medcloud has its own I.A engine in order to help radiologist on their daily basisworkflow. • The MedcloudApp • Medcloud’s App is aimed to provide patients with thebest experience in accessing and sharing exams as well as to bring them benefits with a new digital experience, suchas: ŸAccessing all exams in real time, anytime, anywhere ŸKeeping medical history centralized. It can be shared • with a new doctor whennecessary • Digitally interacting with a specialist in a virtual pre- appointment • Listening to the voice of a diagnostician explaining test The benefits of this technology can be found not only inthe optimization of clinical workflow but also by providing a secure, reliable and uncomplicated way patients can access their test results and share with their doctors. The business model used by the company is SaaS having the diagnosis clinics as their main clients. As the solution is almost plug and play, the laboratories and diagnosis clinics can have a very fast tool to enhance service and provide a closer care of their patients, while at the same time reducing costs. “We’re delighted to see day by day a large number of healthcare companies experience a more secure and intelligent way to manage, store and share clinical data,” says theCEO. Furthermore, the platform can be used as healthcare marketplace and for that the company is currentlyworking in two newdevelopments: Clinical trials – MedCloud empowers patients to have access to the informationin tests. The system can be transformed into a platform to gather information for clinical trials. Patients can easily decide whether to grant access to the results of their test in exchange of financial compensation for the use of this information in clinical trials. Itis a direct channel to valuable information that can help manystudies. Medical Labor marketplace – Diagnosis clinics and laboratories can use the platform to hire remote skilled medical labor to work on tests and diagnosis. Also, thanks to the large volume of information and approaches of Data Science and Big Data, Medcloud provides trivial means of research and scientific analysis for thesake of goodhealth. results in simpleterms ŸFull-time storage of any type ofexams ŸEasy re-appointments and improvement of the Doctor- Patientrelationship By prioritizing the patient at the center of all processes, clinics adopt a loyalty approach, creating a digitalinterface for the engagement of patients and healthprofessionals. Medcloud can be integrated with any equipment, software or medical device and drastically reduces the use ofprinted media by the clinics, favoring the environment with the digital sharing ofdiagnostics. / MAY 2019 /37

40. The PassionateLeadership • Medcloud was founded by Dimas Francisco Silva Jr.who is currently the CEO. Dimas is passionate about great products, teams, and patient experience. He thinks that great products are like a goodmusic. • Speaking highly of this team, he asserts, “It’s an easy and lovely experience and doesn’t need any previousinstruction in order to enjoy it. In order to enable great products, he thinks that only a good orchestration process and a team could deliver such level of quality. In other words, only a good orchestra could provide a good concert. Only a compromised and devoted team could create a winner service.” • Notable Awards andAccreditations • Medcloud has received the following awards over thelast years: • Brazilian Pharma Solutions @ Biominas Brasil 2018 1st place in the Mapping of Innovations carried out byApex- Brasil, Abiquifi and BiominasBrazil. • Frost & Sullivan’s # 1 Cloud-Based Medical Solution in Latin America,’ 2016 Best Practices Award, more thanan award, this title was a confirmation that Medcloud has been on the right track to achieve itsmoonshots. • Also, Medcloud is the only 100% Cloud Platform in the marketwithANVISAand HIPAAcomplianceaccreditation. The Brazilian Health Regulatory Agency (ANVISA) is an autarchy linked to the Ministry of Health; this is hugeand very important for Medcloud’s clients. More than offering a great product, the company aims to provide a safe place to store PHI (Personal HealthcareInformation). Bright Future of Medcloud Medcloud had an exponential growth in the past year. The company is already operating in 19 states inside Brazil,and has special projects in Uruguay, Chile and USA. With that vision, Medcloud has created a new class of products and services. “I.A and Cloud is a natural and required movefor ALL diagnostic centers, clinics and hospitals around the world,” saysDimas. Its desire to conquer the international market has been influenced by its minority partner; an investment fund from New York called Startup Health. Through Startup Health’s coaching and acceleration program, Medcloud managers had the opportunity to see that the innovation environment outside Brazil offers a wide range of possibilities. And the company is currently evaluating possible internationalization scenarios, like Europe, Africa andmore countries and North and SouthAmerica. Also, Medcloud has been partnering with important Teleradiology and Telemedicine groups across South America, to offer their services in a more clinic-oriented way. The goal here is to enable diagnostic centers and hospitals to experience the Cloud and I.A services througha medical and service perspective, rather than a software experience. 38/MAY2019/

42. Never Miss aDose MedicationApps Mmakingtosimplifythelives.Thesemobileappscomeinallshapesandsizesanddoa obile phones, especially smartphones, are doing more than what theywere intendedtodo.Thankstoalltheappsthatdevelopersaroundtheworldarebusy myriadofthingsforsmartphoneusers.Whilegaming,socialmedia,andretailappscontinueto rule the charts, health apps are surely catching up. With people becoming more health consciousthanever,theseappsarealsomakingtheirmark. Goodhealthisattributedtomanyfactors.Oneneedstohaveaproperdiet,exercise,routine checkups,andthelikes.Whatmostpeopletendtoneglectintentionallyorunintentionallyis themedicationroutine.Medicines,beitalifesavingdrugorjustavitaminpill,isalsoessential forgood health.Unfortunately,mostpeopletendtoforgettakingtheirpillsontime.Some blame it on their schedule, some don’t find the time, some are too busy to remember, and some, like the elderly, just forget to take it. According to a report published in Annals of Internal Medicine, September 2012, America loses $100 – $289 billion in a year due to medicationnon-adherence.Thesituationisgraverincaseofchronicillnesses.Treatmentof suchdiseaserequireslong-termuseofmedicines.Butpatientsareseennotadheringtoitdue tovariousreasons.AstudyfromMayoClinicstates“approximately50%ofpatientsdonot taketheirmedicationsasprescribed.”Thisamountstonotonlymonetarylossbutalsohealth issues.Somepatientsendupinemergencyroomsbecausetheydidtakemedicinesontime. Even small issues turn into serious ones if not treated properly. Doctors have long been advisingpeopletotaketheirmedicinesasprescribed.Buttheresultsjustdon’tmatchup. Keeping a digital eye on health Mobileappsarenowbeingusedtofightthisunderratedhealthconcern.Ahugepopulationof thesepatientsusessmartphones.Mobileappsarenowbeingrecommendedbydoctorsand otherpatientsaliketotacklethismenace.Theseappsareeasytouse,mostlyfree,andare designedtoperformalotofthingsforthepatients.Theseappshaveanumberoffeaturesto assist patients with drug adherence. The process is simple and starts with the patient uploadingtheirprescriptionorfillinginthedrugsthattheyareon.Theycanthencustomize alarms,setupemergencynumbers,putatracker,andothersuchfeatures.Someappsevenuse gamestohelppatientsunderstandtheimportanceoftakingmedicationontime. 40 / MAY 2019/

43. Editor'sAngle Apps fullof features Different apps offer different features and sometimes address only a particular concern. Some apps are free of cost while some are premium and offer much-advanced features.But mostappsdothefollowing: Setupreminders--Easiestwaytogetyourdoseon timeistosetupalarms.Theappssetoffalarmsata definitivetimeandsomeevenlightupthescreen with particular colors to remind the patients of theirpendingdose.Some evenauto-adjusttothe time zones, so that the patients do not mess up their dosage when traveling to different parts of theworld. Send messages to caregiver -- Some apps send messagestothepatient’scaregiver(mostlyfamily member)anddoctorwhentheymissadose.They canthenremindthepatienttotaketheirmedicine. / MAY 2019 /41

44. Managefamilyhealth--Someappscanhelppatientsdealwithmultipleprofiles.Thisallowsone membertrackthemedicinehabitsoftheentirefamily. DrugInteraction–Fewappshavethefeaturetoletpatientsknowaboutdruginteractionsi.e.if any two or more of one’s medicines can react and cause issues to his/her wellbeing. This featurecanreallyhelpifonetakesover-the-counterdrugswithprescribedmedicine. MedicalJargons–Mobileappscanletpatientsunderstandmedicaltermstoo.Termslike CR (ControlledRelease)printedonthemedicinecanoftenbeconfusingforpatients.Theseapps helpthemcracksuchcodes. Refillreminders–Thesemobileappsremindpatientsinadvancewhentheyareabouttorun outoftheirprescribedmedicines. ContactingPharmacy--Afewappsletpatientsuploadtheirprescriptionwiththepharmacy andgettheirmedicinesdoor-stepdeliveredwhentheyneedit.Theyevenallowthepharmacy tocross-checkwiththepatient’sdoctortomakesurethattheprescribedmedicinesneedto becontinued. Generic Report – Some medicine mobile apps also let patients record their blood pressure, sugarlevelsandsendthemtotheirdoctorsatafixedtimeinterval(sayonceinamonth). These mobile apps are really proving to be a boon especially for the elderly and those suffering from chronic illnesses or illnesses like Parkinson where the patient genuinely forgets to take the pills. Timely reminders, interactive interface, easy-to-use and manage features,soundsandlights,allmakethemsuitableforpatientsacrosstheworld.Somepaid andadvancedappsevenletpatientstakeavideoconsultationwiththeirdoctors.Theworldis gettingsmarterandbetter.Theworldofmedicineappsisslowlyrecognizingtheopportunity andwhatthismarket canbeinthefuture.Suchappsaresurelygoingto makethisworlda healthierplace! -Sneha Sinha,Editor 42/MAY2019/